Comparative Pharmacology
Head-to-head clinical analysis: LAMIVUDINE NEVIRAPINE ZIDOVUDINE TABLETS versus LAMIVUDINE TENOFOVIR DISOPROXIL FUMARATE NEVIRAPINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LAMIVUDINE NEVIRAPINE ZIDOVUDINE TABLETS versus LAMIVUDINE TENOFOVIR DISOPROXIL FUMARATE NEVIRAPINE.
LAMIVUDINE/NEVIRAPINE/ZIDOVUDINE TABLETS vs LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE; NEVIRAPINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) that inhibits HIV reverse transcriptase by competing with natural substrates and causing chain termination. Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds directly to reverse transcriptase, causing conformational disruption. Zidovudine is an NRTI that inhibits viral reverse transcriptase after intracellular phosphorylation to its active triphosphate form.
Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) that inhibits HIV-1 reverse transcriptase via DNA chain termination after intracellular phosphorylation to lamivudine triphosphate. Tenofovir disoproxil fumarate is a nucleotide reverse transcriptase inhibitor (NtRTI) that, after hydrolysis and phosphorylation, inhibits HIV-1 reverse transcriptase by competing with deoxyadenosine 5'-triphosphate and causing DNA chain termination. Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that directly binds to and inhibits HIV-1 reverse transcriptase, causing a conformational change and reducing enzyme activity.
One tablet (150 mg lamivudine/200 mg nevirapine/300 mg zidovudine) orally twice daily.
One tablet (300 mg lamivudine, 300 mg tenofovir disoproxil fumarate, 400 mg nevirapine) orally once daily. Nevirapine requires a 14-day lead-in dose of 200 mg once daily when initiating therapy.
None Documented
None Documented
Lamivudine: 5-7h (adults), prolonged in renal impairment. Nevirapine: 25-30h (single dose), 40-45h (multiple doses, autoinduction). Zidovudine: 0.5-3h (terminal), prolonged in hepatic impairment.
Lamivudine: 5-7 hours in adults (extended to 20-30 hours in renal impairment). Tenofovir: 17-18 hours in adults (prolonged in renal impairment). Nevirapine: ~45 hours (single dose) to 25-30 hours (multiple doses due to autoinduction).
Lamivudine: ~70% renal (glomerular filtration and tubular secretion, unchanged). Nevirapine: ~80% biliary/fecal (metabolites), ~10% renal (unchanged). Zidovudine: ~75% renal (metabolism to glucuronide, tubular secretion).
Lamivudine: 70% renal (glomerular filtration and tubular secretion) as unchanged drug. Tenofovir: 70-80% renal (glomerular filtration and tubular secretion) as unchanged drug. Nevirapine: ~81% renal (metabolites, <5% unchanged), ~10% fecal.
Category A/B
Category A/B
NRTI
NRTI